NOV.DE Novo Nordisk A/S
P/E
11.767759
Forward P/E
--
Price/Sales
0.58138
Beta
0.36
Div Yield
0.048799999999999996%
Market Cap
--
Company Analysis
Latest News
Novo Nordisk tests Vivani’s semaglutide implant to replace weekly injections
Novo Nordisk partnered with Vivani Medical to evaluate NPM-139, an implantable device for delivering semaglutide. The implant utilizes NanoPortal technology...
Novo Nordisk secures Medicare coverage for Wegovy, expanding access for millions
Medicare begins coverage for specific GLP-1 weight-loss medications on July 1, 2026. This expansion provides millions of eligible seniors access to treatments...